Barbara Bradfield
In 1992 she was the first patient with recurrent HER2-positive breast cancer to be treated with the antibody that became Herceptin, in Dennis Slamon's trial at UCLA. She became its first long-term survivor.
Barbara Bradfield had HER2-positive breast cancer that had recurred and spread when, in 1992, Dennis Slamon at UCLA asked her to join the first clinical trial of the humanised anti-HER2 antibody, later trastuzumab. She initially declined further treatment, then agreed; her disease responded and did not return. Her case, told in Robert Bazell's book Her-2 and dramatised in the 2008 film Living Proof, gave the programme evidence at a moment when its future inside Genentech was uncertain. Trastuzumab was approved by the FDA in 1998 for metastatic HER2-positive disease and, after the adjuvant trials of 2005, for early disease, changing a subtype once regarded as among the worst into one of the more treatable. She remained a public voice for the trial participants whose consent made the drug possible.
Pages like this
not linked directly; found by shared links- PersonRobert Sandler
Shares Trials enrol too few, too slowly and the tags hero, patient.
- PersonSharon Belvin
Shares Trials enrol too few, too slowly and the tags hero, patient.
- PersonBud Romine
Shares Trials enrol too few, too slowly and the tags hero, patient.
- PersonEmily Whitehead
Shares Trials enrol too few, too slowly and the tags hero, patient.
- PersonAlexandra "Alex" Scott
Shares the tags hero, patient.
- PersonAshya King
Shares the tags hero, patient.
- PersonChadwick Boseman
Shares the tags hero, patient.
- PersonEinar "Jimmy" Gustafson
Shares the tags hero, patient.